• Metabolic Enhancement of Ferroptosis and Cuproptosis in Tumo

  2026-05-06

  This article examines a recent metabolic intervention strategy that synchronously sensitizes tumor cells to ferroptosis and cuproptosis, thereby enhancing anti-tumor immunity. The study introduces a nanosystem targeting glycolysis and NAD+ metabolism, offering new mechanistic insights and practical routes for regulated cell death-based cancer therapy.

• Glabridin-Gold(I) Complex Enhances Antitumor Immunity via Tr

  2026-05-06

  This study introduces a novel glabridin-gold(I) complex (6d) that synergistically targets thioredoxin reductase (TrxR) and MAPK pathways to enhance antitumor immunity while mitigating immunosuppression in liver cancer. The findings offer mechanistic insight into dual-pathway modulation and highlight prospects for improved combination immunotherapy strategies.

• L-Ornithine (B8919): Mechanistic Insights for CNS-Liver Rese

  2026-05-05

  Explore the multifaceted role of L-Ornithine in CNS-liver axis research, with new mechanistic insights from recent studies. This article highlights its value in advanced amino acid metabolism research and practical assay design.

• GANT61: GLI Inhibitor Workflows for Tumor Growth Suppression

  2026-05-05

  Leverage GANT61, a selective GLI inhibitor from APExBIO, to dissect Hedgehog pathway signaling, overcome immunotherapy resistance, and suppress tumor growth in advanced cancer models. This guide provides evidence-backed protocols, advanced troubleshooting, and actionable insights that translate the latest bench research into practical workflows.

• Indazole/Indole Glucagon Receptor Antagonists: Synthesis & F

  2026-05-04

  This study reports a novel series of indazole- and indole-based glucagon receptor antagonists with potent in vitro and in vivo activity. Through systematic structure–activity relationship (SAR) studies, the team identified orally active compounds that effectively reduce glucagon-induced hyperglycemia, offering promising leads for type 2 diabetes therapy.

• Caspase-3 Colorimetric Assay Kit: Practical Workflow Guidanc

  2026-05-04

  The Caspase-3 Colorimetric Assay Kit (SKU: K2008) offers a sensitive, rapid solution for quantifying DEVD-dependent caspase-3 activity in apoptosis assays. It is best suited for apoptosis, caspase signaling pathway, and neurodegenerative disease research where robust, reproducible caspase activity measurement is required. This kit should not be used in contexts requiring multiplexed or in vivo detection, or where detailed mechanistic insight beyond DEVD-pNA substrate cleavage is needed.

• Bay 11-7821 in Cancer and Inflammatory Signaling Pathway Res

  2026-05-03

  Bay 11-7821 (BAY 11-7082) is redefining precision targeting of the NF-κB pathway, empowering advanced cancer research and immune modulation. Discover optimized workflows, troubleshooting strategies, and translational insights to maximize its impact in apoptosis regulation and inflammation studies.

• tFUS Suppresses Post-Stroke Neuroinflammation via SHP2 Pathw

  2026-05-02

  This study demonstrates that transcranial focused ultrasound stimulation (tFUS) reduces NLRP3-mediated neuroinflammation following ischemic stroke by modulating the Nespas/miR-383-3p/SHP2 signaling pathway in microglia. These findings establish a mechanistic basis for targeting SHP2 in neuroinflammation and suggest new avenues for translational stroke research.

• Lipoamino Bundle LNPs Optimize mRNA Delivery to Immune Cells

  2026-05-01

  This study introduces lipoamino bundle lipid nanoparticles (LNPs) engineered for highly efficient mRNA transfection of dendritic cells and macrophages, with pronounced spleen targeting in vivo. The findings support advances in mRNA delivery technologies, relevant for immunotherapy and vaccine development.

• Azithromycin: Macrolide Antibiotic Workflows for Research Pr

  2026-05-01

  Azithromycin, a flagship macrolide antibiotic from APExBIO, empowers researchers with robust workflows for bacterial infection models, resistance profiling, and trypanosomosis studies. This article distills evidence-backed protocols, troubleshooting insights, and innovative applications to unlock reproducible results and actionable data.

• NU7441 (KU-57788) DNA-PK Inhibitor: Reliable Tools for DNA R

  2026-04-30

  This article addresses practical laboratory challenges in DNA repair and oncology research, focusing on cell viability and DNA damage response assays. By leveraging the selectivity and potency of NU7441 (KU-57788) DNA-PK inhibitor (SKU A8315), researchers can achieve reproducible and data-backed results. Real-world scenarios, evidence-based recommendations, and protocol guidance are provided to support scientists using this compound in their workflows.

• RP3-340N1.2 Knockdown Limits NSCLC Progression via IL-6 Dest

  2026-04-30

  This study uncovers RP3-340N1.2 as an oncogenic lncRNA in non-small cell lung cancer (NSCLC), promoting tumor growth and migration through stabilization of IL-6 mRNA. Knockdown of RP3-340N1.2 enhances IL-6 mRNA decay via ZC3H12A, suggesting a novel molecular axis for therapeutic intervention in NSCLC.

• Strategic Insights: SOD Activity Assay for Translational Res

  2026-04-29

  Explore the mechanistic and strategic landscape of superoxide dismutase (SOD) activity measurement, with a focus on the APExBIO SOD Activity Assay Kit (K2035). This thought-leadership article bridges biochemical insight with translational imperatives, contextualizes assay selection in light of recent literature on ROS measurement pitfalls, and provides actionable guidance for researchers aiming to advance oxidative stress-driven disease models.

• Mechanistic Strategies for Next-Gen Luciferase mRNA Assays

  2026-04-29

  This thought-leadership article bridges the latest mechanistic insights in lipid nanoparticle (LNP) mRNA delivery with hands-on guidance for translational researchers. Using the advanced EZ Cap™ Firefly Luciferase mRNA from APExBIO as a case study, we explore how Cap 1 structure and poly(A) tail optimization drive performance in gene regulation reporter assays and in vivo bioluminescence imaging. The piece integrates new findings on LNP composition, critically analyzes standard protocols, and sets a roadmap for maximizing translational impact—escalating the discussion beyond typical product guides.

• Endoglin in Endothelial-Astrocyte Crosstalk in Alzheimer’s D

  2026-04-28

  This study uncovers how endothelium-specific endoglin (ENG), released via cerebrovascular extracellular vesicles, drives astrocyte reactivity in Alzheimer’s disease (AD) models. The findings highlight a novel mechanism linking vascular dysfunction to neuroinflammation, with ENG emerging as both a potential biomarker and a therapeutic target.

15626 records 2/1042 page Previous Next 12345 下5页 Last page